WilmerHale Reps Nabriva Therapeutics in $80M Public Offering of Ordinary Shares

WilmerHale Reps Nabriva Therapeutics in $80M Public Offering of Ordinary Shares

Firm News

On September 22, 2017, Nabriva Therapeutics plc (NASDAQ:NBRV) closed on its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $8.50 per share, totaling approximately $80 million.

Brian Johnson led the WilmerHale team representing Nabriva in this transaction, which also included Scott Lunin and Alicia Lee.

Nabriva's announcement regarding the pricing of this offering can be found at www.nabriva.com.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.